How to Buy Avidity Biosciences Stock
Avidity Biosciences Inc
Avidity Biosciences, Inc. , a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases.
Avidity Biosciences stock last closed at $23.83, down 5.02% from the previous day, and has increased 41.59% in one year. It has overperformed other stocks in the Biotechnology industry by 0.65 percentage points. Avidity Biosciences stock is currently +393.89% from its 52-week low of $4.83, and -13.85% from its 52-week high of $27.66.
As of Apr 25, 2024, there are 79.72M RNA shares outstanding. The market value of RNA is $1.90B. In the last 24 hours, 1.24M RNA shares were traded.
How to Buy Avidity Biosciences Stock
Wondering how to invest in Avidity Biosciences stock? Here's how.
- Figure out where to buy Avidity Biosciences stock: You need to decide on a stock brokerage, but don't worry - we've tested dozens of online brokerages and apps to help you determine where to buy Avidity Biosciences stock.
- Open a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
- Deposit funds into your investment account: Select your method of payment and add your info.
- Research Avidity Biosciences stock: The Avidity Biosciences ticker symbol is RNA. Is Avidity Biosciences stock a good investment? Should you buy shares of RNA? How do RNA's underlying business fundamentals look? Do top analysts think Avidity Biosciences is a good buy? Why has RNA's stock price moved recently? (Hint: Our stock market research tools can help you decide if RNA is a good stock to buy).
- Place your RNA buy order: Decide if you will purchase RNA shares at the current market price or use a limit order to buy RNA shares at a particular price.
- Get notifications regarding your investment in RNA: Create a watchlist to monitor your position in Avidity Biosciences shares.
Step 1: Figure out where to buy Avidity Biosciences stock
You need an online brokerage account to access the NASDAQ market and buy RNA stock.
Our recommended brokerage: eToro
Based on our analysis, eToro is the best stock brokerage. Here's why:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to global financial markets: From Tech to Real Estate, New York to London — you can fill your portfolio with stocks from the globe's leading stock exchanges.
- Social investing: eToro offers a community of more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by signing up for an account with eToro today.
Open eToro AccountStep 2: Open a brokerage account
Now that you've picked the best brokerage, the next step is to fill out some personal information so you can buy RNA today.
How to Start a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal data to start your new brokerage account.
- Submit your application by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you have opened your account on stock apps to use, you can securely and quickly fund your account:
Watch this video walkthrough if you need help transferring money into your new brokerage account.
Step 4: Research Avidity Biosciences stock
Once you have selected the best place to buy Avidity Biosciences stock, it's critical to research their stock prior to buying, so you can comprehend the risk and upside.
Avidity Biosciences quick stats
Avidity Biosciences Zen Score
WallStreetZen was designed to help average investors do more accurate fundamental analysis quickly.
You can view all of the due diligence checks on RNA's stock page.
Is RNA stock overvalued?
You can use many financial metrics, analyses, models, and charts to gauge RNA's fair value.
Using relative valuations ratios:
- RNA could be undervalued based on its P/B ratio of 3.79x, relative to Biotechnology industry P/B ratio of 5.8x
You can access additional valuation analysis on RNA's stock here.
RNA Financial Health Summary
Signs that RNA is financially healthy:
- RNA has a low debt to equity ratio of 0.26.
- There are more short-term assets than long-term liabilities on the RNA balance sheet.
- RNA has $595.65M in cash and short term investments. This is enough to cover its annual cash burn of $123.29M.
- RNA has cash burn of 123292000. It has sufficient cash and short-term investments to cover this for at least one year.
- There are more short-term assets than short-term liabilities on the RNA balance sheet.
- Total RNA debt is lower than 5 years ago, relative to shareholder equity.
Signs that RNA is not financially healthy:
- RNA profit margin has gone down from -1,886.3% to -2,219.9% in the past year.
Do Wall Street analysts think it's a good time to buy RNA stock
Out of 4 Wall Street analysts who monitor RNA, the consensus analyst rating on Avidity Biosciences is a Strong Buy
Please keep in mind that analyst forecasts are not stock recommendations, nor are they financial advice.
You can dive deeper into what analysts are forecasting on the Avidity Biosciences stock forecast page.
Metrics for Advanced RNA Traders
How are RNA Revenues/Earnings doing?
Last year, RNA revenue was $9.56M. In the last five year, RNA's revenue has increased by 90.71% per year. This was faster than the Biotechnology industry average of 28.62%.
Find out more about RNA's earnings and revenue performance here.
What are RNA insiders up to?
Over the last 12 months, executives and large shareholders at RNA have sold more shares than they have bought.
Arthur A. Levin, Director of RNA, was the latest RNA insider to sell. They sold $114,125.00 worth of RNA shares on Apr 19, 2024.
Learn more about who owns RNA stock here.
Does RNA stock generate passive income?
No, Avidity Biosciences doesn't provide an income stream by paying out dividends.
What others are saying about RNA
One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other traders have to say.
Step 5: Place your RNA buy order
There are two primary order types:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are usually the best for newer investors. - Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
If you want to make sure you're buying or selling at an exact price limit, use a limit order.
Click the Open Trade button and eToro will place your order.
If you need more help with buying stocks on eToro, click the how to video below:
Step 6: Get notifications regarding your investment in RNA
Now that you own some RNA stock, you'll want to keep up with your new investment.
Start a watchlist to keep track of your RNA stock.
RNA Feed
How to Buy Stock in Avidity Biosciences
To summarize, here are the 6 steps for buying Avidity Biosciences stock:
- Figure out where to buy Avidity Biosciences stock
- Open a brokerage account
- Deposit funds into your investment account
- Research Avidity Biosciences stock
- Place your RNA buy order
- Get notifications regarding your investment in RNA
If you require a brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you want to get updates on your new investment in Avidity Biosciences, create a watchlist today.
Other Stock Buying Guides You May Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.